← Company directoryNASDAQ · SEC EDGAR
NeuroSense Therapeutics Ltd.
NRSNA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
NeuroSense Therapeutics 1-for-20 reverse share split
NeuroSense Therapeutics shares will begin post-split trading on Nasdaq on 14 September following a 1-for-20 reverse share split. The new CUSIP will be M74240207; fractional shares will be rounded up to the nearest whole share.
SEC EDGAR ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
NRCNRC HealthNASDAQ · SEC→NRDSNerdWallet, Inc.NASDAQ · SEC→NRIMNorthrim BanCorp IncNASDAQ · SEC→NRIXNurix Therapeutics, Inc.NASDAQ · SEC→NRSNWNeuroSense Therapeutics Ltd. - WarrantNASDAQ · SEC→NRXPNRX Pharmaceuticals, Inc.NASDAQ · SEC→NSAIUNorthStrive Acquisition Corp I. - UnitsNASDAQ · SEC→NSITInsight Enterprises, Inc.NASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.